Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure

• Status: Terminated
• Trial end date: 2019-02-25
• Target enrollment: 0
• Participant gender: All

Summary

Phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dova Pharmaceuticals

Criteria

Inclusion Criteria:

• Men and women greater than or equal to 18 years of age;

• A mean baseline platelet count between:

• 50 × 10^9/L and <100 × 10^9/L for non-chronic liver disease participants

• 50 × 10^9/L and <75 × 10^9/L for participants with chronic liver disease;

• Participant is scheduled to undergo operations to critical sites (eg, eye surgery, neurosurgery) or operations with a high risk of bleeding (eg, major abdominal surgery), or, in the opinion of the Investigator, would otherwise require a pre-operative platelet transfusion to prevent bleeding

Exclusion Criteria:

• Participant with a history of arterial or venous thrombosis within 6 months of baseline;

• Participant with known portal vein blood flow velocity rate <10 cm/second or previous portal vein thrombosis within 6 months of baseline;

• Participant plans to have a platelet transfusion or plans to receive blood products containing platelets within 7 days of the Baseline Visit;

• Use of erythropoietin-stimulating agents;

• Participant has a known medical history of genetic prothrombotic syndromes; or

• Participant has abnormal hemoglobin levels or prothrombin time/international normalized ratio